Literature DB >> 23986347

In reply.

Antonis Valachis, Nikolaos P Polyzos.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23986347      PMCID： PMC3755942          DOI： 10.1634/theoncologist.2013-0235

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  11 in total

1.  Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro.

Authors:  G van der Pluijm; H Vloedgraven; E van Beek; L van der Wee-Pals; C Löwik; S Papapoulos
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

2.  Role of zoledronate in aromatase activity should be considered in future studies.

Authors:  Mohamed Amin Ghobadifar
Journal:  Oncologist       Date:  2013

3.  γδ T cells predict outcome in zoledronate-treated breast cancer patients.

Authors:  Joanne L Welton; Salvador Martí; Mohammed H Mahdi; Clare Boobier; Peter J Barrett-Lee; Matthias Eberl
Journal:  Oncologist       Date:  2013

4.  Zoledronic acid and its accentuating effect on tumor radiosensitivity.

Authors:  Shailendra Kapoor
Journal:  Oncologist       Date:  2013

5.  Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer.

Authors:  M Gallo; A De Luca; L Lamura; N Normanno
Journal:  Ann Oncol       Date:  2011-05-06       Impact factor: 32.976

6.  Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.

Authors:  Florence Daubiné; Céline Le Gall; Juerg Gasser; Jonathan Green; Philippe Clézardin
Journal:  J Natl Cancer Inst       Date:  2007-02-21       Impact factor: 13.506

7.  Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis.

Authors:  Antonis Valachis; Nikolaos P Polyzos; Robert E Coleman; Michael Gnant; Holger Eidtmann; Adam M Brufsky; Rebecca Aft; Amye J Tevaarwerk; Karen Swenson; Pehr Lind; Davide Mauri
Journal:  Oncologist       Date:  2013-02-12

8.  Zoledronic acid sensitizes renal cell carcinoma cells to radiation by downregulating STAT1.

Authors:  Toshiki Kijima; Fumitaka Koga; Yasuhisa Fujii; Soichiro Yoshida; Manabu Tatokoro; Kazunori Kihara
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

9.  In vitro synergistic cytoreductive effects of zoledronic acid and radiation on breast cancer cells.

Authors:  A Ugur Ural; Ferit Avcu; Muhammed Candir; Metin Guden; M Ali Ozcan
Journal:  Breast Cancer Res       Date:  2006       Impact factor: 6.466

10.  Bisphosphonates induce apoptosis in human breast cancer cell lines.

Authors:  S G Senaratne; G Pirianov; J L Mansi; T R Arnett; K W Colston
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.